Flura-seq for Evaluating the Effects of Different Hyperthermic Intraperitoneal Chemotherapy Regimens on the Transcriptome of Pseudomyxoma Peritonei

Inclusion Criteria

• Age 18-75 years old, regardless of gender and race;
• Pathologically confirmed as pseudomyxoma peritonei; acceptable for CRS+HIPEC treatment;
• KPS score ≥ 60, with expected survival time more than 12 months;
• The functions of important organs are basically normal, with no significant abnormalities in liver or kidney function;
• No history of allergy to biological products;
• No serious bacterial or viral infection;
• Non-pregnancy and lactation;
• The patient or his/her delegate understands and cooperates with the treatment and signs the informed consent for the treatment.

Exclusion Criteria

• Highly allergic or with a history of severe allergies, especially to biological products;
• Shock, systemic failure, unstable vital signs, and inability to cooperate with the examination;
• Those who have mental or psychological diseases and cannot cooperate with treatment and curative effect evaluation;
• T-lymphocyte carcinoma/tumor;
• Patients with systemic infection or severe local infection requiring anti-infection treatment;
• Complicated with dysfunction of heart, lung, brain, kidney, liver and other important organs;
• Coagulation disorders (e.g., hemophilia);
• Infectious diseases (e.g. HIV, RPR, active TB, etc.);
• Pregnant or lactating women, or women who have pregnancy plans within half a year;
• Patients who are taking immunosuppressive drugs or long-term anti-rejection drugs after organ transplantation;
• Patients with severe autoimmune diseases;
• Any life-threatening disease, physical condition or organ system dysfunction that the researcher believes may damage the safety of subjects and expose the research results to unnecessary risks; Drug-dependent persons;
• Patients and/or authorized family members who refuse or do not actively sign the informed consent;
• Participants in other clinical studies within 3 months.